Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 5/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TTR | P02766 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.55 |
| ▸ | THRA | P10827 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1204414 | 0.88 | HTT (0.72) | TPMTHSD17B10KMT2ATSHRAPOBEC3A | |
| SCHEMBL30740894 | 0.88 | HTT (0.72) | TPMTHSD17B10KMT2ATSHRAPOBEC3A | |
| SCHEMBL31063258 | 0.87 | TPMT (0.67) | TPMTHSD17B10KMT2ATTRTSHR | |
| SCHEMBL29198878 | 0.87 | TPMT (0.67) | TPMTHSD17B10KMT2ATTRTSHR | |
| SCHEMBL21837048 | 0.87 | TPMT (0.67) | TPMTHSD17B10KMT2ATTRTSHR | |
| SCHEMBL1560980 | 0.87 | TPMT (0.67) | TPMTHSD17B10KMT2ATTRTSHR | |
| SCHEMBL31318522 | 0.87 | TPMT (0.67) | TPMTHSD17B10KMT2ATTRTSHR | |
| SCHEMBL7670073 | 0.85 | TPMT (0.65) | TPMTHSD17B10KMT2ATTRTSHR | |
| SCHEMBL1302354 | 0.84 | TPMT (0.63) | TPMTHSD17B10KMT2ATTRTSHR | |
| SCHEMBL31318546 | 0.82 | TPMT (0.61) | TPMTHSD17B10KMT2ATTRTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113943228-B | Alkaloid pulmonin B derivative, synthesis thereof and application thereof in preventing and treating plant virus and germ diseases | 天津师范大学 | 2023-10-27 | — | — | CN | claimed |
| US-20260070923-A1 | METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION CONTAINING SAME COMPOUND, AND HYDRATE OF SAME COMPOUND | JW PHARMACEUTICAL CORP (KR) | 2026-03-12 | — | — | US | disclosed |
| US-12497410-B2 | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | JW PHARMACEUTICAL CORPORATION (KR) | 2025-12-16 | — | — | US | disclosed |
| WO-2025224674-A1 | ALICHONDRICHLORIN FOR USE IN TREATING CANCER | CIIMAR - CENTRO INTERDISCIPLINAR DE INVESTIGAÇÃO MARINHA E AMBIENTAL (PT) | 2025-10-30 | — | — | WO | disclosed |
| CN-119143779-A | Process for preparing heterocyclic derivative compounds, compositions containing the compounds and hydrates of the compounds | JW 制药公司 | 2024-12-17 | — | — | CN | disclosed |
| EP-3909956-B1 | HYDROCHLORIDE SALT 1.5 HYDRATE OF AN HETEROCYCLIC DERIVATIVE COMPOUND | JW PHARMACEUTICAL CORP (KR) | 2024-12-04 | — | — | EP | disclosed |
| CN-119059989-A | URAT1 inhibitor, preparation method and application thereof | 中国药科大学 | 2024-12-03 | — | — | CN | disclosed |
| US-12103938-B2 | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | JW PHARMACEUTICAL CORPORATION (KR) | 2024-10-01 | — | — | US | disclosed |
| CN-114085235-B | Process for preparing heterocyclic derivative compounds, compositions containing the compounds and hydrates of the compounds | JW 制药公司 | 2024-08-13 | — | — | CN | disclosed |
| US-12030895-B2 | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | JW PHARMACEUTICAL CORPORATION (KR) | 2024-07-09 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| EP-1077969-A1 | BENZOTHIOPHENES, BENZOFURANS, AND INDOLES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999061435-A1 | BENZOTHIOPHENES, BENZOFURANS, AND INDOLES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-02 | — | — | WO | disclosed |
| US-5861416-A | TREATMENT OF ASTHMA OR COUGH | MERRELL PHARMACEUTICALS INC. (US) | 1999-01-19 | — | — | US | disclosed |
| US-5824690-A | TREATING ASTHMA, COUGH | HOECHST MARION ROUSSEL INC. (US) | 1998-10-20 | — | — | US | disclosed |
| US-5661160-A | ADMINISTERING AN ANTITUSSIVE AGENT FOR TREATING COUGH; TACHYKININ ANTAGONISM, SUBSTANCE P AND NEUROKININ A ANTAGONISM | MERRELL PHARMACEUTICALS INC. (US) | 1997-08-26 | — | — | US | disclosed |
| US-5648366-A | TACHYKININ ANTAGONISTS USEFUL IN TREATING ASTHMA | MERRELL PHARMACEUTICALS INC. (US) | 1997-07-15 | — | — | US | disclosed |
| US-5635510-A | TACHYKININ (ESPECIALLY SUBSTANCE P AND NEUROKININ A) ANTAGONISTS; ANTIINFLAMMATORY AGENTS, ANALGESICS; NERVOUS SYSTEM DISORDERS; BRONCHODILATOR AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1997-06-03 | — | — | US | disclosed |
| US-4274998-A | Diester of 3,5,3',5'-tetrabromo-bisphenol A with halogenated aromatic carboxylic acid | ASAHI-DOW LIMITED (JP) | 1981-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12103938-B2 | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | REN, NOD1, NLRP3 | TPMT 187/4885HSD17B10 1328/4885KMT2A 2874/4885 |
| US-20260070923-A1 | METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION CONTAINING SAME COMPOUND, AND HYDRATE OF SAME COMPOUND | SLC26A3, SLC10A6, SLC14A1 | TPMT 120/4885HSD17B10 441/4885KMT2A 2561/4885 |
| US-12497410-B2 | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | REN, NOD1, NLRP3 | TPMT 187/4885HSD17B10 1328/4885KMT2A 2874/4885 |
| US-12030895-B2 | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | REN, NOD1, NLRP3 | TPMT 187/4885HSD17B10 1328/4885KMT2A 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.